Published in FASEB J on June 28, 2010
A new era of secreted phospholipase A₂. J Lipid Res (2015) 1.08
Liver X receptors and fat cell metabolism. Int J Obes (Lond) (2012) 0.93
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages. Arterioscler Thromb Vasc Biol (2010) 0.84
Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival. Mol Cancer (2013) 0.83
Hair follicular expression and function of group X secreted phospholipase A2 in mouse skin. J Biol Chem (2011) 0.83
Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function. J Biol Chem (2011) 0.80
Group X secretory phospholipase A2 regulates insulin secretion through a cyclooxygenase-2-dependent mechanism. J Biol Chem (2014) 0.79
Integrated lipidomics in the secreted phospholipase A(2) biology. Int J Mol Sci (2011) 0.79
Group X Secreted Phospholipase A2 Releases ω3 Polyunsaturated Fatty Acids, Suppresses Colitis, and Promotes Sperm Fertility. J Biol Chem (2016) 0.78
The Role of Phospholipase A(2)-derived Mediators in Obesity. Drug Discov Today Dis Mech (2010) 0.77
Transcriptome analysis of hen preadipocytes treated with an adipogenic cocktail (DMIOA) with or without 20(S)-hydroxylcholesterol. BMC Genomics (2015) 0.76
Ectopically expressed pro-group X secretory phospholipase A2 is proteolytically activated in mouse adrenal cells by furin-like proprotein convertases: implications for the regulation of adrenal steroidogenesis. J Biol Chem (2015) 0.75
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
Obesity as a medical problem. Nature (2000) 15.12
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev (1994) 10.44
Dynamics of fat cell turnover in humans. Nature (2008) 9.80
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell (1999) 9.74
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev (2000) 9.09
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell (1975) 8.29
Obesity-induced inflammatory changes in adipose tissue. J Clin Invest (2003) 7.50
Role of LXRs in control of lipogenesis. Genes Dev (2000) 6.98
Identification of white adipocyte progenitor cells in vivo. Cell (2008) 6.58
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev (1996) 6.54
Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis. J Biol Chem (2000) 3.59
Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem (2002) 3.58
Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem (2008) 2.94
Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res (2000) 2.92
Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia (2007) 2.71
Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol (2001) 2.68
Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res (1994) 2.58
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol (2002) 2.44
The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am (2008) 2.20
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol (1999) 2.05
Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated transcription. Mol Cell Biol (1997) 1.97
Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol (1993) 1.92
Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol (2006) 1.90
AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med (2009) 1.88
Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab (2009) 1.79
Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol (2004) 1.74
Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem (1997) 1.59
OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. J Lipid Res (2005) 1.58
Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem (2001) 1.57
Modulation of the murine peroxisome proliferator-activated receptor gamma 2 promoter activity by CCAAT/enhancer-binding proteins. J Biol Chem (2000) 1.52
LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem (2005) 1.44
Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J Biol Chem (2008) 1.42
Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem (1997) 1.28
Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes (2006) 1.27
On the role of liver X receptors in lipid accumulation in adipocytes. Mol Endocrinol (2003) 1.26
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem (2006) 1.25
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem (2002) 1.22
Biology of secretory phospholipase A2. Cardiovasc Drugs Ther (2008) 1.17
Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem (2005) 1.13
Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J Lipid Res (2004) 1.11
Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation (2008) 1.09
Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie (2005) 1.04
Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem (2010) 1.03
Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J (2010) 1.03
The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br J Pharmacol (2009) 1.03
Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta (2006) 1.02
Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor. Arch Biochem Biophys (2000) 0.99
The new concept of adipose tissue function. Physiol Behav (2004) 0.99
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J (2006) 0.97
Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands. J Biol Chem (2010) 0.89
Gene expression profiling in adipose tissue indicates different transcriptional mechanisms of liver X receptors alpha and beta, respectively. Biochem Biophys Res Commun (2003) 0.86
Lipoatrophic diabetes: a case report with a brief review of the literature. J Adolesc Health (2008) 0.77
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol (2007) 1.89
Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis (2010) 1.48
HDL cholesterol transport during inflammation. Curr Opin Lipidol (2007) 1.45
HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol (2008) 1.40
Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation (2013) 1.23
High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem (2004) 1.21
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol (2004) 1.18
High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif. J Biol Chem (2005) 1.17
Biology of secretory phospholipase A2. Cardiovasc Drugs Ther (2008) 1.17
Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. J Lipid Res (2007) 1.15
Perinatal exercise improves glucose homeostasis in adult offspring. Am J Physiol Endocrinol Metab (2012) 1.13
Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol (2008) 1.11
Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J (2011) 1.07
Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J Biol Chem (2005) 1.06
Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. J Lipid Res (2005) 1.01
Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J Lipid Res (2008) 0.99
Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res (2003) 0.99
Scavenger receptor SR-BI in macrophage lipid metabolism. Atherosclerosis (2011) 0.97
Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res (2011) 0.97
Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res (2010) 0.95
Lipid rafts in cytokine signaling. Cytokine Growth Factor Rev (2004) 0.93
SAA does not induce cytokine production in physiological conditions. Cytokine (2012) 0.91
The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol (2009) 0.91
Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2013) 0.91
Thematic review series: The immune system and atherogenesis. Cytokine regulation of macrophage functions in atherogenesis. J Lipid Res (2005) 0.90
Group X secretory phospholipase A2 regulates the expression of steroidogenic acute regulatory protein (StAR) in mouse adrenal glands. J Biol Chem (2010) 0.89
Quantitative analysis of SR-BI-dependent HDL retroendocytosis in hepatocytes and fibroblasts. J Lipid Res (2006) 0.88
Differential localization of IL-2- and -15 receptor chains in membrane rafts of human T cells. J Leukoc Biol (2002) 0.88
ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res (2010) 0.87
Calpain II colocalizes with detergent-insoluble rafts on human and Jurkat T-cells. Biochem Biophys Res Commun (2002) 0.86
Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J Lipid Res (2011) 0.86
Effect of increased body mass index on asthma risk, impairment and response to asthma controller therapy in African Americans. Curr Med Res Opin (2010) 0.86
Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J (2010) 0.85
The Impairment of Macrophage-to-Feces Reverse Cholesterol Transport during Inflammation Does Not Depend on Serum Amyloid A. J Lipids (2013) 0.85
Getting to the core of atherosclerosis. Nat Med (2008) 0.84
Lipid rafts, major histocompatibility complex molecules, and immune regulation. Hum Immunol (2002) 0.84
Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages. Arterioscler Thromb Vasc Biol (2010) 0.84
Recommendations of the 6th long-term oxygen therapy consensus conference. Respir Care (2006) 0.83
SR-BI selective lipid uptake: subsequent metabolism of acute phase HDL. Arterioscler Thromb Vasc Biol (2009) 0.83
Long-term continuous oxygen treatment in chronic obstructive pulmonary disease: proper use, benefits and unresolved issues. Curr Opin Pulm Med (2007) 0.83
Lack of a direct role for macrosialin in oxidized LDL metabolism. J Lipid Res (2003) 0.83
Clinical use of exhaled biomarkers in COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.82
Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines. Cytokine (2010) 0.82
SR-BI-mediated selective lipid uptake segregates apoA-I and apoA-II catabolism. J Lipid Res (2005) 0.82
Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages. J Immunol (2011) 0.79
Tubulin polymerization modulates interleukin-2 receptor signal transduction in human T cells. J Recept Signal Transduct Res (2006) 0.78
Group V secretory phospholipase A2 enhances the progression of angiotensin II-induced abdominal aortic aneurysms but confers protection against angiotensin II-induced cardiac fibrosis in apoE-deficient mice. Am J Pathol (2012) 0.78
Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol (2006) 0.77
Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain. J Investig Med (2005) 0.76
Public-private partnership: complementary efforts to improve oral health. J Calif Dent Assoc (2014) 0.75
Readers' perspectives. Federal agencies have moved too slow to create policies that support President Bush's goal of electronic medical records. Health Data Manag (2006) 0.75
National COPD conference summary. COPD (2004) 0.75
Using FTE and RVU performance measures to assess financial viability of academic nurse-managed centers. Nurs Econ (2004) 0.75